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PERSPECTIVE
How could patient reported outcomes improve patient management in chronic
myeloid leukemia?
Federico De Marchi, Marta Medeot, Renato Fanin and Mario Tiribelli
Division of Hematology and BMT, Department of Experimental and Clinical Medical Sciences, Azienda Sanitaria Universitaria Integrata di Udine,
Udine, Italy
ABSTRACT
Introduction: Patients reported outcome (PRO) are still under-used in patients with chronic myeloid
leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), though data on the correlation between
quality of life (QoL) and therapeutic efficacy are increasingly known. Chronic low-grade toxicities can
reduce patient’s QoL and negatively impact on adherence.
Areas covered: This review will focus on the role of QoL questionnaires in patients with CML, receiving
imatinib or newer TKIs (dasatinib, nilotinib, bosutinib, ponatinib). Physicians tend to underestimate the
impact of TKI-related symptoms, in particular fatigue, that negatively affect QoL and can be a reason of
poor adherence to therapy, with detrimental effect on long-term response. Few studies pointed out the
role of PRO in CML, and there is paucity of questionnaires specifically designed for CML patients.
Expert commentary: We recommend a wider use of PRO to join the pursuit of a rapid and deep
responses with an optimization of QoL.
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1. Introduction
Chronic myeloid leukemia (CML) is a clonal disorder of hema-
topoietic stem cell characterized by the presence of
Philadelphia chromosome (Ph+), resulting in the fusion gene
BCR-ABL [1].
Treatment and prognosis of CML has radically changed
with the introduction of tyrosine-kinase inhibitors (TKIs), the
first example of highly effective target therapy in onco-hema-
tology [2]. TKIs have significantly increased life-expectancy in
CML, and patients treated with imatinib, the TKI with longest
follow-up, have a survival close, if note equal, to that of
general population [3]. The TKI success has therefore made
CML therapy similar to that of other chronic diseases, in which
the most important aspect is the continuative, daily, drug
taking, with serial monitoring of BCR/ABL transcript, a specific
and reliable marker of response to treatment [4]. Adherence to
therapy is emerging as one of the pivotal aspects in CML
treatment, as even a slight reduction in taken TKI seems to
negatively impact on response [5]. It is important to underline
as each different TKI has a peculiar safety profile with char-
acteristic side effect, both in the short and long term, that can
impact on adherence to therapy and quality of life (QoL) [6].
Imatinib’s most common toxicities are peripheral edema, nau-
sea, muscle cramps, and muscle-skeletal pain [7], while long-
term toxicities of second- and third-generation TKIs are still to
be accurately defined, with some notable exception such as
peripheral arterial obstructive disease (PAOD) for nilotinib and
pleural effusion for dasatinib [8,9]. However, though TKIs have
improved QoL compared with previous CML therapy, such as
interferon or chemotherapy [10], TKI treatment is associated
with a worsening in QoL and symptoms reported by patients
are often more serious than how they are perceived by phy-
sicians [11]. Generally, QoL is evaluated with specific question-
naires that are filled by the patients during the course of
treatment. The importance and relevance of these question-
naires is highlighted by a large, population-based study invol-
ving about half a million people included in the UK population
biobank project, showing that self-reported health was the
strongest predictor of survival among all the analyzed factors
[12]. Self-reported QoL has been proved to impact on overall
survival (OS) in various clinical conditions spanning from neo-
plastic diseases [13], arthritis [14], obstructive pulmonary dis-
eases [15], hemodialysis [16], HIV infection [17] and in more
than 2,000 elderly patients from a large integrated-delivery
network in the USA [18]. Patient-reported outcomes (PRO)
are defined as the measurement of every aspect of patient’s
health, including disease-related symptoms, autonomy, dis-
ease and therapy perception, toxicities or adverse events,
physical, psychological, and social aspects, all as reported
from the patient him/herself without any second-party inter-
pretation. PRO can be used to identify and quantify various
aspects of patient’s status, ranging from pain intensity to
overall health quality [19]. The questionnaires consist of doz-
ens (usually more than thirty) of questions, aimed to evaluate
different aspects of individual well-being [20,21].
As PRO have demonstrated in different settings a prognos-
tic value in terms of survival, it would be of great interest to
evaluate if specific interventions aimed to improve related
outcomes could impact on life expectancy. PRO seems to
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influence the chance of a patient-physician communication on
symptoms during outpatient visits, resulting in a better control
of the same symptoms and consequently an improved
patient’s satisfaction [22,23].
2. PRO in hematological malignancies
QoL questionnaires are gaining importance in hematologic
disorders and, in few cases, were already included in consen-
sus conferences and guidelines. A Canadian study on 445
patients with high-risk myelodysplastic syndromes (MDS)
demonstrated that patient-reported fatigue, quantified by a
validated questionnaire (EORTC QLQ-C30) [24], independently
predicts OS and was superior as predictors compared to
widely used scores (IPSS or IPSS-R) based on objective para-
meters such as number of cytopenias, blast count or cytoge-
netics [25]. In MDS, it would be of interest to verify if QoL is
associated with risk of evolution to AML or what is the impact
of QoL questionnaires in low-risk MDS patients. In this latter
setting, it has been found that low-intermediate risk 5q-
patients benefit from lenalidomide therapy due to a reduction
in red-cell transfusion frequency and increased hemoglobin
levels, resulting in a better reported QoL; this subjective ben-
efit persists over time, justifying long-term treatment [26].
In multiple myeloma (MM), the same EORTC QLC-C30 ques-
tionnaire was included in a randomized trial (NMSG 4/90)
comparing melphalan/prednisone versus melphalan/predni-
sone plus alpha-2b interferon alph-2b in newly diagnosed
patients [27]. Physical and cognitive functioning, pain, fatigue
and reported QoL were associated, in univariate analysis, with
survival; in multivariate analysis, physical functioning and
WHO-defined performance status emerged as independent
prognostic factors, and the best risk stratification was obtained
by combining physical functioning score with an objective,
measurable data (i.e. beta-2 microglobulin). An impact of
QoL questionnaires on the outcome of myeloma patients has
been confirmed in another study (SUMMIT) evaluating 202
patients with resistant/refractory MM treated with proteasome
inhibitor bortezomib. Patients enrolled received four question-
naires (EORTC, QLQ C30, QLQ MY24 e FACT GOG Ntx [24,28–
31]) at different time points. QoL scores obtained were not
only associated with survival, but also with response to treat-
ment, while reported QoL progressively declined in patients
with progressive disease [32]. PRO thus helped in interpreting
response to treatment.
QoL questionnaires permitted also to extrapolate various
evidences that could impact on treatment and clinical
practice of hematological neoplasms. In acute myeloid leu-
kemia (AML) patients, physical exercise during hospitaliza-
tion for induction chemotherapy has a positive impact on
QoL by reducing symptoms and fatigue [33]. In patients
with low-intermediate risk acute promyelocytic leukemia
(APL), induction therapy with all-trans retinoic acid (ATRA)
plus arsenic trioxide (ATO) is equally effective than ATRA
plus chemotherapy but is superior in terms of QoL, thus
emerging as standard induction therapy [34]. In myelofi-
brosis patients, a ≥ 50% improvement from baseline in
symptom score during treatment with ruxolitinib had a
key role in US FDA full approval to the drug [35]. In a
British study on 431 chronic lymphocytic leukemia (CLL)
patients, a reduction in PRO scores has been associated
with disease-related symptoms, recommending to start
treatment in patients experiencing symptomatic disease,
to improve QoL [36,37].
The use of the specific Medical Outcomes Study Short Form
36 questionnaire [38] prior to in 336 patients predicts overall
mortality after transplant independently and as well as other
commonly used non-PRO indexes [39]. In the same study, a
reduction in the score early after HSCT was associated with an
increased overall mortality and treatment-related mortality.
Moreover, PRO gave also nonclinical information, underlining
for example that, in the USA, patients receiving HSCT experi-
ence a reduction in QoL due to transplant-generated econom-
ical restraints, reported by specific questionnaires [40].
In summary, inclusion of PRO during treatment can result in
incorporation of patient’s point of view in a comprehensive
evaluation, with improvement in the clinical management.
QoL questionnaires may give independent prognostic infor-
mation, beside traditional clinical parameters. PRO could
impact also on survival, as they allow an earlier recognition
of disease-related symptoms, or when used to implement
further therapies aimed at QoL improvement and to adequate
therapies to perceived side effects.
3. PRO in CML
Few studies have focused on QoL in patients with CML receiv-
ing TKIs (Table 1), though five different drugs (imatinib, nilo-
tinib, dasatinib, bosutinib, and ponatinib) have been approved
for first- or second-line therapy [41] and though these drugs
are designed for life-time use, at least until treatment-free
remission studies would give definitive results for drug dis-
continuation in selected cases [42]. TKIs guarantee a survival
not significantly inferior compared to normal people’s, and no
differences in progression-free survival (PFS) and OS at 5 years
have been reported for patients receiving imatinib, dasatinib,
or nilotinib, even if safety profiles of the three drugs differ
[43,44]. It is therefore evident the importance of a tool able
precisely report on patient’s QoL, symptoms, side effects and
drug tolerability of long-lasting, daily treatments.
3.1. Imatinib
PRO have been used to evaluate QoL in CML patients treated
with imatinib; the pivotal IRIS study, that led to approval of
front-line use of imatinib, showed that TKI was superior to
interferon alfa plus low-dose cytarabine, also in terms of QoL
[10]. However, the multicenter Imatinib Long-Term (side)
Effects (ILTE) study, analyzing more than 800 patients treated
with imatinib for a median of almost 6 years, found out that
about half of the patients experienced side effects interfering
with daily activities [3]. Efficace et al. compared QoL profiles of
general population and of 448 patients receiving imatinib with
favorable response. After a median of 5 years of therapy, the
commonest reported symptom was fatigue (82%), while at
least a third of patients complained of fluid retention and
pain; the biggest QoL differences were found in younger
(18–39 years) and female patients [45]. Interestingly,
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symptoms reported by patients are more intense than what is
perceived by the treating physician.
An analysis on 442 dyads of questionnaires on health status
and symptom severity completed by CML patients on imatinib
therapy and by their physicians showed an agreement on
symptoms ranging from 34% (muscle cramps) to 66% (nausea)
[11]. Patients reported higher severity on all the evaluated
symptoms, and fatigue was the most frequently underesti-
mated by physicians (51%), that overestimated general health
status in two-third of patients. This study suggest that the use
of PRO could enhance the management of CML patients, as
the main cause of non-adherence to treatment, a critical factor
on achievement of optimal response to imatinib [46], is the
attempt to avoid side effects [47–49].
3.2. Second-generation TKIs
Data on second-generation TKIs are scantier and uneven [50],
derived mainly from studies utilizing various PRO and different
end points. From the ENESTnd study, comparing nilotinib and
imatinib as frontline treatment, incidence rate of low-grade
adverse events was lower in nilotinib arm, but nonetheless
impacting on QoL in terms of psychiatric and so called ‘gen-
eral’ disorders [51]. In the UK SPIRIT2 trial, comparing first-line
dasatinib and imatinib, no significant differences emerged in
terms of reported QoL, but data’s limited details do not allow
for definitive conclusions [52]. Regarding bosutinib, Trask et al.
reported an improvement in physical and emotional well-
being in imatinib-resistant or -intolerant CML patients at 24
and 48 months after bosutinib start [53].
Few studies focused on a real-life setting, however confirm-
ing a reduction of perceived QoL during TKI therapy, an
association between QoL and treatment satisfaction, and a
possible increase of QoL with prolongation of therapy [54–56].
3.3. Value of different QoL questionnaires
As a general consideration, PRO used in most studies have not
been designed specifically for CML patients. In the past years,
some leukemia-specific QoL instruments have been devel-
oped. The Functional Assessment of Cancer Therapy –
Leukemia (FACT-Leu) [57] combines a general QoL scale
(FACT-G) with a specific subscale designed for acute and
chronic leukemia, comprising both physical, emotional and
social items. Though quite extensive (44 items) the FACT-Leu
has proven to be a reliable tool to assess patients’ perceived
health and useful in both clinical research and every-day
practice [58]. The MD Anderson Symptom Inventory (MDASI)-
CML [59] is the evolution of the MDASI, an instrument
designed to evaluate how common symptoms of cancer and
its treatment infer with daily activities [60]. Compared to its
general counterpart, the CML-specific questionnaire is com-
posed of 7 items derived from interview of 35 CML patients
and subsequently validated in 152 patients longitudinally fol-
lowed at MD Anderson Cancer Center. The main strengths of
this item are its briefness and the numeric scale of symptom
grading, that can be easily understood, translated into other
languages and administered by telephone or electronically. In
2014, the European Organization for Research and Treatment
of Cancer designed a disease-specific QoL questionnaire for
CML patients, the EORTC QLQ-CML24 [61]. It is the result of a
three-step process of generation of health-related QoL issues
relevant for CML by literature review and interviews with
health-care professionals and patients, construction of 30-
items provisional questionnaire, and test of the questionnaire
in a large cohort of patients form 10 countries (USA, Europe
and Asia). The final result is a module of 24 items covering
symptom burden, impact on daily life and on mood, percep-
tion of body image, satisfaction with care and with social life.
EORTC QLQ-CML24 is a patient-centered approach that may
bypass the under-estimation of symptom’s intensity by treat-
ing physicians.
Systematic and standardized implementation of this speci-
fic tool could help the physician in correctly interpreting
patient-reported symptoms, resulting in a possible improve-
ment of therapy and patient’s satisfaction [62].
4. Expert commentary
Despite having been introduced since more than 10 years in
neoplastic and chronic diseases, QoL PRO are less used in
hematological malignancies. In CML, in particular, the suc-
cesses of target therapy may have in some way shifted the
focus from the patient to the diseases. Hundreds of studies
have reported the efficacy of imatinib first-, and then of sec-
ond- and third-generation TKIs, in terms of cytogenetic and
molecular responses, long-term survival and even treatment-
free remission, while only a handful of papers focused on
patient-reported physical and psychological symptoms, fears,
and expectations. Far from neglecting the capital importance
Table 1. Summary of studies focusing on QoL in patients with CML receiving TKIs.
First
author Patient selection Treatment
Number of
patients Main results
Hahn CP-CML frontline IMA 400 vs. IFN-LDAC 1049 Physical function and well-being superior with IMA (even after
cross-over)
Efficace CP-CML frontline in CCyR IMA 400 (78%)
IMA ≠ 400 (22%)
448 Worst QoL impairment in young pts and females; fatigue most
reported
Efficace CP-CML frontline in CCyR IMA 400 (78%)
IMA ≠ 400 (22%)
442 Fatigue is the symptom most often underestimated by physicians
Guérin CP-CML frontline IMA 400 vs. NILO 600–800 593 AEs similar or lower for NILO than IMA
Labeit CP-CML frontline IMA 400 vs. DASA 100 812 No differences between DASA and IMA in QoL
Trask CP-CML after IMA failure BOSU 500 271 Little improvement or no changes during BOSU tx
CP-CML: chronic-phase chronic myeloid leukemia; CCyR: complete cytogenetic response; IFN-LDAC: interferon plus low-dose cytarabine; IMA: imatinib;
NILO: nilotinib; DASA: dasatinib; BOSU: bosutinib; QoL: quality of life; pts: patients; AEs: adverse events; tx: therapy.
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of objective and measurable responses, we just want to point
out that the patient’s perspective might have been under-
evaluated. As demonstrated by the work of Efficace et al.
[11], physicians perceived a lower severity for all symptoms
than their CML patients, while overestimating patients’ health
status in two-third of the cases. This misperception can be
really detrimental, as the excellent results of TKI therapy are
linked to a regular assumption of these oral drugs. The under-
estimation of treatment side effect, even mild (the so-called
grade 0–I toxicities) but affecting patient QoL, such as fatigue
and pain, may generate in patients a sensation of not being
properly listened to, that can cause lack of adherence. The
search for quick and deep responses, prerequisites for favor-
able progression-free and overall survival, should be ideally
gathered with an optimization of QoL, as the latter is impact-
ing on the former when long-term oral therapy is involved. In
this scenario, physicians must rely on PRO, as no one can
better describe his/her symptoms and feeling as the patient.
5. Five-year view
PRO implementation in CML patients could provide information
useful for the management of TKI therapy and generate data
potentially impacting on disease course. To date, QoL question-
naires consist of numerous questions that demand a significant
amount of time to be answered, and this is hardly compatible
with the time generally allowed for a follow-up visit. Thus, we
expect that, in the next years, easier questionnaires will be
designed, so that patients can complete them at home and
return them at the following visit. To increase response rate and
patients’ compliance, it is of paramount importance for the
physician to explain in detail to patients how important are
careful and sincere answers to QoL questionnaires. To extrapo-
late from PRO data useful information in a reasonable time,
patient’s answers should be summed up in synthetic classes,
expression of the total of single scores, with the aim to give
clinician a global picture of patient’s well-being.
Once the methodic is standardized and routinely used in the
out-patient practice, the use of CML-specific PRO at various
time-points of therapy (i.e. baseline, after 3, 6, and 12 months
and yearly thereafter) will define if QoL during continuous TKI
treatment is inferior to general population, in which symptoms
and amount. This could also help to identify candidates to drug
discontinuation, not only according to a deep and sustained
molecular response but also considering the burden of treat-
ment on QoL.
A better definition of QoL will allow us to more efficiently
follow CML patients over time, with a prompt detection of
symptoms and, consequently, a rapid intervention, resulting in
an increased compliance and patient’s satisfaction. As non-
compliance of oral medications seems to be mostly aimed to
avoid side effects, a rapid detection of patient reported symp-
toms could positively impact on adherence to TKI therapy, a
prerequisite for optimal response. Along with a favorable
impact on long-term survival, ‘PRO-induced’ adherence may
have also a positive economic repercussion, as more patients
could achieve a sustained deep molecular response, thus
becoming candidate for treatment discontinuation. More,
PRO might be used to define which TKI has a better
tolerability profile in specific CML subset (younger or elderly
patients, patients with comorbidities, etc.). This data, in asso-
ciation with the well-standardized response parameters, may
help us in finding an answer to the still open question ‘What is
the best TKI for this particular patient given the excellent
therapies available?’ [63].
Beside large-scale implementation, it will be necessary to
design drug-specific questionnaires, as different TKIs have dif-
ferent safety profiles, so questions aimed at detecting early
symptoms related to a certain inhibitor could give treating
physician a supplement information. As a matter of fact, with
such effective therapies the QoL of CML patients is impacted
more by side effects of TKIs than by disease itself [64].
Finally, it would be of great interest to analyze potential
correlations between perceived health and objective para-
meters, such as molecular response. Is it possible that a
given PRO is associated with a specific therapeutic response?
If the case, QoL questionnaires could be combined with
response criteria in a dynamic prognostic score, to identify
patients that should continue the therapy in use, those who
should change dosage or TKI, or even the candidates to treat-
ment discontinuation.
Key issues
● Five different tyrosine kinase inhibitors (TKIs) targeting BCR-
ABL oncoprotein are approved for the treatment of patients
with chronic myeloid leukemia (CML).
● TKIs are effective and, generally, well tolerated, though
long-term data are still scanty for second- (dasatinib, niloti-
nib, bosutinib) and third- (ponatinib) generation TKIs.
● Chronic low-grade toxicities during TKI therapy can reduce
patient quality of life (QoL) and thus negatively impact on
adherence.
● Physician often tend to underestimate symptoms, such as
fatigue and pain.
● Lack of recognition and poor treatment of therapy-related
symptoms may cause reduced adherence to treatment,
with negative consequences on response.
● Patient reported outcomes (PRO) are associated with
improved symptom control, increased patient satisfaction
and, in most cancer clinical trials, longer overall survival (OS).
● The use of QoL PRO in CML patients is still limited, and
generally derived from studies of imatinib; even less is
known on PRO in patients treated with second- and third-
generation TKIs.
● The development and dissemination of questionnaires spe-
cifically designed for CML patients (such as MDASI-CML and
EORTC QLQ-CML24) is warranted to define the benefits of
TKIs and optimize treatment.
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